GANX - Gain Therapeutics Inc
IEX Last Trade
1.1
0.030 2.727%
Share volume: 555,763
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.07
0.03
2.80%
Fundamental analysis
23%
Profitability
25%
Dept financing
9%
Liquidity
62%
Performance
15%
Performance
5 Days
-15.50%
1 Month
-1.80%
3 Months
-56.57%
6 Months
-75.56%
1 Year
-68.31%
2 Year
-67.85%
Key data
Stock price
$1.10
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.89 - $5.33
52 WEEK CHANGE
-$0.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO:
Region: US
Website: gaintherapeutics.com
Employees: 27
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gaintherapeutics.com
Employees: 27
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.
Recent news